ストックスクリーナーアプリを入手
4.28
6.55%
-0.30
プレマーケット:
4.29
0.010
+0.23%
前日終値:
$4.58
開ける：
$4.62
24時間の取引高:
1.79M
Relative Volume:
0.92
時価総額：
$409.38M
収益：
$829.00M
当期純損益:
$-399.90M
株価収益率:
-0.9917
EPS:
-4.3159
ネットキャッシュフロー:
$-23.20M
1週間 パフォーマンス:
+1.18%
1か月 パフォーマンス:
+34.17%
6か月 パフォーマンス:
-8.35%
1年 パフォーマンス:
-46.43%
1日の値動き範囲:
$4.22
$4.826
1週間の範囲:
$4.055
$4.826
52週間の値動き範囲:
$2.74
$8.59
Myriad Genetics Inc Stock (MYGN) Company Profile
名前
Myriad Genetics Inc
セクター
電話
801-584-3600
住所
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, NTRA, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
4.28 | 398.86M | 829.00M | -399.90M | -23.20M | -4.3159 |
TMO
Thermo Fisher Scientific Inc
|
656.58 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.61 | 150.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
400.65 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
169.33 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
436.43 | 42.59B | 3.77B | 449.25M | 240.68M | 7.8556 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-21 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-12 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | 開始されました | Craig Hallum | Buy |
| 2024-12-10 | 開始されました | UBS | Neutral |
| 2024-12-09 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-06-27 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-03 | 再開されました | Jefferies | Underperform |
| 2024-05-08 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | 再開されました | Piper Sandler | Neutral |
| 2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Underweight |
| 2023-05-23 | アップグレード | Goldman | Sell → Buy |
| 2023-01-18 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 開始されました | Stephens | Equal-Weight |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-06-15 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-03 | 開始されました | Goldman | Sell |
| 2019-09-26 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2019-07-29 | ダウングレード | Needham | Strong Buy → Hold |
| 2019-07-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2019-03-12 | 繰り返されました | Needham | Strong Buy |
| 2019-01-03 | 開始されました | Needham | Strong Buy |
| 2018-11-30 | アップグレード | Goldman | Sell → Neutral |
| 2018-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 開始されました | Goldman | Sell |
| 2018-01-22 | 繰り返されました | Barclays | Equal Weight |
| 2018-01-05 | 開始されました | BTIG Research | Buy |
| 2017-10-02 | 再開されました | Leerink Partners | Mkt Perform |
| 2017-08-09 | 繰り返されました | Barclays | Equal Weight |
| 2017-02-08 | アップグレード | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 開始されました | Deutsche Bank | Sell |
| 2016-10-10 | ダウングレード | Ladenburg Thalmann | Neutral → Sell |
すべてを表示
Myriad Genetics Inc (MYGN) 最新ニュース
Form 4 Myriad Genetics Inc For: 27 September By Investing.com - Investing.com Canada
Myriad Genetics, Inc. (MYGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Myriad Genetics, Inc. (MYGN) stock price, news, quote and history - Yahoo Finance Australia
3 Reasons MYGN is Risky and 1 Stock to Buy Instead - Yahoo Finance
Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product Segments - GlobeNewswire Inc.
Myriad Genetics stock falls after guidance reset and weak Q2 figures - AD HOC NEWS
Myriad Genetics (MYGN) ex-CCO keeps stock-tied PSUs - Stock Titan
Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating the Challenges in Diagnostics & Research - DirectorsTalk Interviews
Myriad Genetics (MYGN) Stock Fair Value Moves Lower After Analyst Cuts And Guidance Reset - Yahoo Finance
Myriad Genetics Inc. (MYGN) Key Financial Ratios – Valuation, Profitability & More - Value Research
Form 8K Myriad Genetics Inc For: 17 September By Investing.com - Investing.com India
Myriad Genetics (NASDAQ: MYGN) Confirms 2026 Financial Outlook Amid Executive Commercial Leadership Shift - Kalkine Media
Myriad Genetics names Vishal Sikri as EVP, commercial - Medical Buyer
Myriad Genetics promotes Vishal Sikri to commercial chief By Investing.com - Investing.com South Africa
Myriad Genetics promotes Vishal Sikri to commercial chief - Investing.com
Myriad Genetics (NASDAQ: MYGN) swaps commercial chief but keeps 2026 outlook - Stock Titan
Myriad Genetics Appoints Vishal Sikri Executive Vice PresidentCommercial - Yahoo Finance
Myriad Genetics And 2 Other Penny Stocks To Consider - simplywall.st
Myriad Genetics at Wells Fargo conference: cancer focus amid pressure By Investing.com - Investing.com Canada
MYGN Maintained by UBS -- Price Target Lowered to $3.60 - GuruFocus
UBS Adjusts Price Target on Myriad Genetics to $3.60 From $6, Keeps Neutral Rating - Yahoo Finance
Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN) - Yahoo Finance
Myriad Genetics Inc. (MYGN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
BlackRock arm now owns more than a tenth of Myriad Genetics (NASDAQ: MYGN) - Stock Titan
Myriad Genetics Inc. (MYGN) Peer Comparison – Compare with Others - Value Research
Stocks making big moves yesterday: Myriad Genetics, Greenbrier, Tidewater, Strategy, and Charter - Yahoo Finance
Why Myriad Genetics (MYGN) Stock Is Down Today - Yahoo Finance
Myriad Genetics stock downgraded at Piper Sandler (MYGN:NASDAQ) - Seeking Alpha
Myriad Genetics Stock Gets Double-Downgrade as Profitability Concerns Grow - Barron's
Myriad Genetics shares fall 7.1% after Piper Sandler downgrade - finance.yahoo.com
Why is Myriad Genetics stock tumbling today? By Investing.com - Investing.com South Africa
Why is Myriad Genetics stock tumbling today? - Investing.com
Piper Sandler cuts Myriad Genetics stock rating on profit concerns By Investing.com - Investing.com Nigeria
Piper Sandler Downgrades Myriad Genetics(MYGN.US) to Sell Rating, Cuts Target Price to $2 - Moomoo
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference - GlobeNewswire
Myriad Genetics and Moderna Shares Plummet, What You Need To Know - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect - ACCESS Newswire
Burning Rock and Myriad Announce Global Strategic Technology Lice - The National Law Review
MYGN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Myriad Genetics Inc. - accessnewswire.com
MYGN Maintained by Stephens & Co. -- Price Target Lowered to $3. - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Myriad Genetics, Inc. MYGN Stock Forecast & Price Target - Yahoo Finance
Marquis Who's Who Honors Ben Wheeler for Expertise in Finance and Healthcare - 24-7 Press Release Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Myriad Genetics (MYGN): Glenview Capital and Larry Robbins report exit from stake - Stock Titan
Myriad Genetics (MYGN): Vestal Point Capital discloses 6.1% stake in 13G filing - Stock Titan
Myriad Genetics Faces Multiple Investor Investigations - stl.news
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
Dimensional Fund Advisors LP Reduces Stake in Myriad Genetics, Inc. $MYGN - MarketBeat
Myriad Genetics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Myriad Genetics Inc (MYGN) 財務データ
収益
当期純利益
現金流量
EPS
0.99%
0.56%
大文字化:
|
ボリューム (24 時間):